Minerva Surgical (NASDAQ:UTRS) Downgraded by Zacks Investment Research

Minerva Surgical (NASDAQ:UTRSGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. Minerva Surgical is based in SANTA CLARA, Calif. “

Separately, Piper Sandler lowered their price objective on Minerva Surgical from $12.00 to $6.00 in a report on Thursday, May 12th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Minerva Surgical presently has an average rating of “Buy” and an average price target of $10.50.

Shares of Minerva Surgical stock traded up $0.12 on Wednesday, hitting $2.35. The company’s stock had a trading volume of 11,767 shares, compared to its average volume of 50,285. The company has a debt-to-equity ratio of 1.13, a current ratio of 2.32 and a quick ratio of 1.72. Minerva Surgical has a 1 year low of $1.61 and a 1 year high of $10.37. The firm has a fifty day moving average price of $3.89 and a 200-day moving average price of $5.23.

Minerva Surgical (NASDAQ:UTRSGet Rating) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.07). Sell-side analysts predict that Minerva Surgical will post -1.24 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in shares of Minerva Surgical during the 4th quarter worth approximately $54,000. Renaissance Technologies LLC acquired a new position in shares of Minerva Surgical during the 4th quarter worth approximately $78,000. BlackRock Inc. acquired a new position in shares of Minerva Surgical during the 4th quarter worth approximately $88,000. Millennium Management LLC acquired a new position in shares of Minerva Surgical during the 4th quarter worth approximately $134,000. Finally, Ghisallo Capital Management LLC acquired a new position in shares of Minerva Surgical during the 4th quarter worth approximately $386,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

About Minerva Surgical (Get Rating)

Minerva Surgical, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.

See Also

Get a free copy of the Zacks research report on Minerva Surgical (UTRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.